Detection of anti-drug antibodies to aflibercept by enzyme-linked immunosorbent assay: Development and validation of the method
Open Access
- 29 September 2025
- journal article
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 25 (3) , 284-295
Abstract
INTRODUCTION. Aflibercept is used to treat neovascular age-related macular degeneration, a leading cause of vision loss. Immunogenicity is one of the significant adverse effects that results in the production of anti-drug antibodies (ADAs). The development of a method for detecting ADAs to aflibercept is essential for immunogenicity assessment.AIM. This study aimed to develop and validate an analytical method for detection and stepwise characterisation of total anti-drug antibodies to aflibercept in human serum utilising the enzyme-linked immunosorbent assay.MATERIALS AND METHODS. The method was developed using a solid-phase ELISA. Aflibercept (GNR-098, JSC GENERIUM, Russia) and a conjugate of GNR-098 with horseradish peroxidase were employed. Polyclonal antibodies against GNR-098 were obtained by immunising rats, followed by serum collection and antibody purification via affinity chromatography. ADA detection was performed using labelled GNR-098 in a bridging ELISA. Model samples were prepared by spiking pooled sera from healthy donors with rat polyclonal antibodies. Method validation included the following parameters: cut-off points; precision; limit of detection (LOD); drug tolerance; specificity; matrix effect; minimum required dilution; robustness; reagent stability; hook effect.RESULTS. An analytical method includes a screening assay for the presumptive detection of ADAs; a confirmatory assay to establish ADA specificity and assay for ADA titer determination and IgE isotyping. The cut-off points for the screening assay and IgE-specific assay were 1.3 and 1.2, respectively; for the confirmatory assay, 15.2%. The LOD of the screening assay was 185 ng/mL. The method demonstrated drug tolerance (interference from soluble target, hrVEGF165) at concentrations up to 2,000 pg/mL. No matrix effects were observed in the screening or confirmatory assays across 13 test samples containing ADAs at 280 ng/mL. The absence of a hook effect was confirmed in both assays using samples with ADA concentrations five times higher than the high-positive control.CONCLUSIONS. An analytical method was developed for the ELISA-based detection and stepwise characterisation of total anti-drug antibodies to aflibercept (GNR-098) in human serum. The method’s suitability was confirmed through validation. This analytical procedure will facilitate the immunogenicity assessment of aflibercept.Keywords
This publication has 10 references indexed in Scilit:
- Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal AntibodiesBioDrugs, 2024
- Age-Related Macular DegenerationJAMA, 2024
- Intraocular neutralizing antibodies against aflibercept in patients with age related macular degenerationBMC Ophthalmology, 2023
- Immunogenicity: Clouding the Future of Intravitreal TherapyOcular Immunology and Inflammation, 2022
- Designing antibodies as therapeuticsCell, 2022
- Anti-VEGF Drugs Dynamics: Relevance for Clinical PracticePharmaceutics, 2022
- A Review of Aflibercept Treatment for Macular DiseaseOphthalmology and Therapy, 2021
- Assessing the Immunogenicity of BiopharmaceuticalsBioDrugs, 2016
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsJournal of Immunological Methods, 2008